Validity and responsiveness of a brief, asthma-specific quality-of-life instrument in children with acute asthma

Marc H. Gorelick, David C. Brousseau, Martha Wood Stevens

Research output: Contribution to journalArticle

Abstract

Objective: To test the validity and short-term responsiveness to change of a pediatric, asthma-specific, health-related quality-of-life (HRQL) instrument. Methods: Children 2 years and older treated in the emergency department (ED) for acute asthma were eligible for this prospective cohort study. A 10-item instrument, the Integrated Therapeutics Group Child Asthma Short Form (ITG-CASF), was administered at the time of the ED visit and again 14 days later (via telephone). At the follow-up call, parents were also asked about the child's current overall asthma status, missed school or limited activities, and persistence of asthma symptoms. Results: A total of 121 children were enrolled (mean age, 7.9 years), and follow-up was complete for 96 (79%). Mean ± SD ITG-CASF scores at follow-up were significantly higher among children reported to have improved overall (61.8 ± 19.6) than those not improved (41.9 ± 21.2), and there was a significant correlation between ITG-CASF score at follow-up and the number of days of school missed or limited activities (r = -0.45; 95% confidence interval [CI], -0.24 to -0.66). There was also a significant difference in improvement in ITG-CASF score from ED visit to follow-up among those improved (13.7-point improvement) compared with those not improved (3.3-point improvement; difference = 10.4; 95% CI, 1.2 to 19.5). The effect size was 0.68, indicating a large responsiveness to change. Conclusions: The ITG-CASF is a valid and responsive measure of HRQL in children with acute asthma and may be a useful outcome measure in evaluating ED treatment.

Original languageEnglish (US)
Pages (from-to)47-51
Number of pages5
JournalAnnals of Allergy, Asthma and Immunology
Volume92
Issue number1
StatePublished - Jan 2004
Externally publishedYes

Fingerprint

Asthma
Quality of Life
Hospital Emergency Service
Confidence Intervals
Therapeutics
Emergency Treatment
Telephone
Cohort Studies
Parents
Outcome Assessment (Health Care)
Prospective Studies
Pediatrics

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

Validity and responsiveness of a brief, asthma-specific quality-of-life instrument in children with acute asthma. / Gorelick, Marc H.; Brousseau, David C.; Stevens, Martha Wood.

In: Annals of Allergy, Asthma and Immunology, Vol. 92, No. 1, 01.2004, p. 47-51.

Research output: Contribution to journalArticle

@article{b93e07af74a2432abbae883d5f81857e,
title = "Validity and responsiveness of a brief, asthma-specific quality-of-life instrument in children with acute asthma",
abstract = "Objective: To test the validity and short-term responsiveness to change of a pediatric, asthma-specific, health-related quality-of-life (HRQL) instrument. Methods: Children 2 years and older treated in the emergency department (ED) for acute asthma were eligible for this prospective cohort study. A 10-item instrument, the Integrated Therapeutics Group Child Asthma Short Form (ITG-CASF), was administered at the time of the ED visit and again 14 days later (via telephone). At the follow-up call, parents were also asked about the child's current overall asthma status, missed school or limited activities, and persistence of asthma symptoms. Results: A total of 121 children were enrolled (mean age, 7.9 years), and follow-up was complete for 96 (79{\%}). Mean ± SD ITG-CASF scores at follow-up were significantly higher among children reported to have improved overall (61.8 ± 19.6) than those not improved (41.9 ± 21.2), and there was a significant correlation between ITG-CASF score at follow-up and the number of days of school missed or limited activities (r = -0.45; 95{\%} confidence interval [CI], -0.24 to -0.66). There was also a significant difference in improvement in ITG-CASF score from ED visit to follow-up among those improved (13.7-point improvement) compared with those not improved (3.3-point improvement; difference = 10.4; 95{\%} CI, 1.2 to 19.5). The effect size was 0.68, indicating a large responsiveness to change. Conclusions: The ITG-CASF is a valid and responsive measure of HRQL in children with acute asthma and may be a useful outcome measure in evaluating ED treatment.",
author = "Gorelick, {Marc H.} and Brousseau, {David C.} and Stevens, {Martha Wood}",
year = "2004",
month = "1",
language = "English (US)",
volume = "92",
pages = "47--51",
journal = "Annals of Allergy, Asthma and Immunology",
issn = "1081-1206",
publisher = "American College of Allergy, Asthma and Immunology",
number = "1",

}

TY - JOUR

T1 - Validity and responsiveness of a brief, asthma-specific quality-of-life instrument in children with acute asthma

AU - Gorelick, Marc H.

AU - Brousseau, David C.

AU - Stevens, Martha Wood

PY - 2004/1

Y1 - 2004/1

N2 - Objective: To test the validity and short-term responsiveness to change of a pediatric, asthma-specific, health-related quality-of-life (HRQL) instrument. Methods: Children 2 years and older treated in the emergency department (ED) for acute asthma were eligible for this prospective cohort study. A 10-item instrument, the Integrated Therapeutics Group Child Asthma Short Form (ITG-CASF), was administered at the time of the ED visit and again 14 days later (via telephone). At the follow-up call, parents were also asked about the child's current overall asthma status, missed school or limited activities, and persistence of asthma symptoms. Results: A total of 121 children were enrolled (mean age, 7.9 years), and follow-up was complete for 96 (79%). Mean ± SD ITG-CASF scores at follow-up were significantly higher among children reported to have improved overall (61.8 ± 19.6) than those not improved (41.9 ± 21.2), and there was a significant correlation between ITG-CASF score at follow-up and the number of days of school missed or limited activities (r = -0.45; 95% confidence interval [CI], -0.24 to -0.66). There was also a significant difference in improvement in ITG-CASF score from ED visit to follow-up among those improved (13.7-point improvement) compared with those not improved (3.3-point improvement; difference = 10.4; 95% CI, 1.2 to 19.5). The effect size was 0.68, indicating a large responsiveness to change. Conclusions: The ITG-CASF is a valid and responsive measure of HRQL in children with acute asthma and may be a useful outcome measure in evaluating ED treatment.

AB - Objective: To test the validity and short-term responsiveness to change of a pediatric, asthma-specific, health-related quality-of-life (HRQL) instrument. Methods: Children 2 years and older treated in the emergency department (ED) for acute asthma were eligible for this prospective cohort study. A 10-item instrument, the Integrated Therapeutics Group Child Asthma Short Form (ITG-CASF), was administered at the time of the ED visit and again 14 days later (via telephone). At the follow-up call, parents were also asked about the child's current overall asthma status, missed school or limited activities, and persistence of asthma symptoms. Results: A total of 121 children were enrolled (mean age, 7.9 years), and follow-up was complete for 96 (79%). Mean ± SD ITG-CASF scores at follow-up were significantly higher among children reported to have improved overall (61.8 ± 19.6) than those not improved (41.9 ± 21.2), and there was a significant correlation between ITG-CASF score at follow-up and the number of days of school missed or limited activities (r = -0.45; 95% confidence interval [CI], -0.24 to -0.66). There was also a significant difference in improvement in ITG-CASF score from ED visit to follow-up among those improved (13.7-point improvement) compared with those not improved (3.3-point improvement; difference = 10.4; 95% CI, 1.2 to 19.5). The effect size was 0.68, indicating a large responsiveness to change. Conclusions: The ITG-CASF is a valid and responsive measure of HRQL in children with acute asthma and may be a useful outcome measure in evaluating ED treatment.

UR - http://www.scopus.com/inward/record.url?scp=1642577218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642577218&partnerID=8YFLogxK

M3 - Article

C2 - 14756464

AN - SCOPUS:1642577218

VL - 92

SP - 47

EP - 51

JO - Annals of Allergy, Asthma and Immunology

JF - Annals of Allergy, Asthma and Immunology

SN - 1081-1206

IS - 1

ER -